Evans Syndrome Market - Granular Market Report and Review, 2018

Market Synopsis of the Global Evans Syndrome Market
Evans syndrome (ES), is an autoimmune disorder characterized by the subsequent or simultaneous development of autoimmune hemolytic anemia, and immune thrombocytopenia. It is classified as primary or secondary based on its association with others diseases, such as primary antiphospholipid syndrome, systemic lupus erythematous (SLE), Sjögren syndrome, Hodgkin lymphoma, IgA deficiency, and chronic lymphocytic leukemia.
According to the Centers for Disease Control & Prevention, autoimmune disorder is the third most common category of disease in the United States after heart disease and cancer. It is reported that it affects approximately 5%–8% of the population i.e. 14–22 million persons.
The severity and symptoms of Evans syndrome vary greatly from one person to another. Some patients with Evans syndrome may first show the high destruction of red blood cells (RBCs), known as anemia, and others may first show low levels of platelets, known as thrombocytopenia. Low levels of white blood cells (WBSs), known as neutropenia, is less common in individuals with Evans syndrome than thrombocytopenia or anemia.
Notably, growing public awareness is the key factor driving the Evans syndrome market. Nowadays, people are becoming more aware of the different types of autoimmune disorders. Government and other different organizations have started educating people about hygiene and diseases through seminars, and conferences. People are becoming more aware and conscious of the diseases. Thus, increasing awareness has provided a push to the growth of the market.
Various other factors such as increasing incidents of autoimmune disorders, increasing government assistance, improving regulatory framework, increasing automation of laboratories and rising funding and reimbursement are continuously contributing to the growth of the global Evans syndrome market.
Despite these drivers, there are some issues associated with Evans syndrome market. Some of the challenges in research and development, side-effects of treatment, the presence of misbranded and spurious drugs, and poor healthcare system in low and middle-income countries, may hinder the growth of the market to an extent.
It is estimated that the Evans syndrome market is expected to grow at a CAGR 10.2% during the forecast period of 2017-2023.
Key Players
Some of key the players in the global Evans syndrome market are Pfizer, Merck & Co., Sanofi, Astellas Pharma, Inc., GlaxoSmithKline plc, Novartis AG, Enzon Pharmaceuticals, Inc., Bayer AG, Sigma-Aldrich, Abbott Laboratories, Eli Lily and Company, BD, ChemoMetec A/S, and Others.
Segmentation
The global Evans syndrome market is segmented on the basis of diagnosis, treatment, and distribution channels.
On the basis of the diagnosis, the market is classified as blood test, bone marrow biopsy, antibody assays, computed tomography (CT) scan, flow cytometry of double-negative T cells, and others. The blood test is further segmented into complete blood count (CBC), and direct antiglobulin test.
On the basis of the treatment, the market is classified as pharmacologic therapy, splenectomy,
Biologic therapy, stem cell transplantation, and others. The pharmacologic therapy is further segmented into Prednisone and intravenous immunoglobulin (IVIg) therapy. The biologic therapy is segmented into Rituximab and others.
On the basis of the distribution channel, the market is segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies, and others.
Regional Analysis
The Americas dominate the Evans syndrome market owing to the rising awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
Europe holds the second position in the Evans syndrome market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in the healthcare is likely to drive the market of Europe region.
Asia Pacific is the fastest growing Evans syndrome market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.
The Middle East & Africa holds the lowest market due to lack of technical knowledge and poor medical facilities.

Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/evans-syndrome-market-5136   

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Evans Syndrome Market - Granular Market Report and Review, 2018

Market Synopsis of the Global Evans Syndrome Market
Evans syndrome (ES), is an autoimmune disorder characterized by the subsequent or simultaneous development of autoimmune hemolytic anemia, and immune thrombocytopenia. It is classified as primary or secondary based on its association with others diseases, such as primary antiphospholipid syndrome, systemic lupus erythematous (SLE), Sjögren syndrome, Hodgkin lymphoma, IgA deficiency, and chronic lymphocytic leukemia.
According to the Centers for Disease Control & Prevention, autoimmune disorder is the third most common category of disease in the United States after heart disease and cancer. It is reported that it affects approximately 5%–8% of the population i.e. 14–22 million persons.
The severity and symptoms of Evans syndrome vary greatly from one person to another. Some patients with Evans syndrome may first show the high destruction of red blood cells (RBCs), known as anemia, and others may first show low levels of platelets, known as thrombocytopenia. Low levels of white blood cells (WBSs), known as neutropenia, is less common in individuals with Evans syndrome than thrombocytopenia or anemia.
Notably, growing public awareness is the key factor driving the Evans syndrome market. Nowadays, people are becoming more aware of the different types of autoimmune disorders. Government and other different organizations have started educating people about hygiene and diseases through seminars, and conferences. People are becoming more aware and conscious of the diseases. Thus, increasing awareness has provided a push to the growth of the market.
Various other factors such as increasing incidents of autoimmune disorders, increasing government assistance, improving regulatory framework, increasing automation of laboratories and rising funding and reimbursement are continuously contributing to the growth of the global Evans syndrome market.
Despite these drivers, there are some issues associated with Evans syndrome market. Some of the challenges in research and development, side-effects of treatment, the presence of misbranded and spurious drugs, and poor healthcare system in low and middle-income countries, may hinder the growth of the market to an extent.
It is estimated that the Evans syndrome market is expected to grow at a CAGR 10.2% during the forecast period of 2017-2023.
Key Players
Some of key the players in the global Evans syndrome market are Pfizer, Merck & Co., Sanofi, Astellas Pharma, Inc., GlaxoSmithKline plc, Novartis AG, Enzon Pharmaceuticals, Inc., Bayer AG, Sigma-Aldrich, Abbott Laboratories, Eli Lily and Company, BD, ChemoMetec A/S, and Others.
Segmentation
The global Evans syndrome market is segmented on the basis of diagnosis, treatment, and distribution channels.
On the basis of the diagnosis, the market is classified as blood test, bone marrow biopsy, antibody assays, computed tomography (CT) scan, flow cytometry of double-negative T cells, and others. The blood test is further segmented into complete blood count (CBC), and direct antiglobulin test.
On the basis of the treatment, the market is classified as pharmacologic therapy, splenectomy,
Biologic therapy, stem cell transplantation, and others. The pharmacologic therapy is further segmented into Prednisone and intravenous immunoglobulin (IVIg) therapy. The biologic therapy is segmented into Rituximab and others.
On the basis of the distribution channel, the market is segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies, and others.
Regional Analysis
The Americas dominate the Evans syndrome market owing to the rising awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
Europe holds the second position in the Evans syndrome market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in the healthcare is likely to drive the market of Europe region.
Asia Pacific is the fastest growing Evans syndrome market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.
The Middle East & Africa holds the lowest market due to lack of technical knowledge and poor medical facilities.

Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/evans-syndrome-market-5136   

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Cowden Syndrome Market 2018 Global– Key Players, Size, Trends, Growth- Analysis To 2023

Market Scenario:

Cowden syndrome is part of the PTEN hamartoma tumor syndrome. Cowden syndrome is characterized by a high risk of both benign and cancerous tumors of the breast, thyroid, endometrium, colorectal, kidney, and skin. The global Cowden syndrome market is expecting a healthy growth in the coming future. The global market is majorly driven by increasing Cowden syndrome patients across the globe. Additionally, increasing smoking population and rising consumption of alcohol have spurred the growth of the market. However, long time for approval and side effects of the treatment may hinder the growth of the market.

The global Cowden syndrome market is expected to grow at a CAGR of 6.7% during the forecast period 2017-2023.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/5096

Key Players

Some of key the players in the market are Amgen, Inc. (U.S.), Eli Lilly and Company (U.S.), AstraZeneca Plc. (U.K.), Bristol-Myers Squibb Company (U.S.), Sanofi (France), AbbVie Inc. (U.S.), Spectrum Pharmaceuticals Inc. (U.S.), Novartis AG (Switzerland), GlaxoSmithKline Plc. (U.K.), Bayer AG (Germany), Takeda Pharmaceuticals (Japan), Pfizer, Inc. (U.S.), Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Janssen Biotech, Inc. (U.S.), Immunomedics (U.S.), and Oncomed Pharmaceuticals (U.S.)

Regional Analysis

The Americas dominate the global Cowden syndrome market owing to the increasing prevalence of people suffering from Cowden syndrome and cancer. Additionally, high healthcare expenditure, well-developed technology, and strong government support for research & development have fuelled the growth of the Americas Cowden syndrome market. Presence of the leading players and increasing availability of funds in this region are likely to support the growth in the coming future.

On the other hand, the Middle East & Africa hold the least share of the market due to limited availability of funds and availability of medical facilities, and poor political conditions in Africa. The Middle East holds the major share in the Middle East & Africa Cowden syndrome market. Kuwait, Qatar, Oman, and South Arabia holds the major share of the Middle East market. However, the African region is expecting a healthy growth due to the presence of a huge opportunity for the development of the market.

And The Europe accounts for the second largest Cowden syndrome market, which is followed by the Asia Pacific. Availability of the funds for research & development and strong government support have driven the market growth. The Asia Pacific is the fastest growing Cowden syndrome market owing to the increasing prevalence of cancer, rapidly developing the economy and increasing government support. India and China are expected to lead the market in this region.

Segmentation

The global Cowden syndrome market is segmented on the basis of site, treatment and end users.

On the basis of the site, the market is segmented into the breast, thyroid, endometrium (uterus), colorectal, kidney, skin (melanoma), and others.

On the basis of the treatment, the market is categorized into genetic testing, chemotherapy, surgery & radiation therapy, targeted therapy, hormone therapy, biologic therapy, and other. The chemotherapy is further segmented into anthracyclines, taxanes, antimetabolites, and alkylating agents. The targeted therapy is sub-segmented with monoclonal antibodies and tyrosine kinase inhibitors. Hormone therapy is further segmented into selective estrogen-receptor modulators (SERMs), aromatase inhibitors, and others.

On the basis of end users, the market is segmented into hospital & clinics, ambulatory care centers, and others.

Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/cowden-syndrome-market-5096

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Agnosia Treatment Market Share, Opportunities, Segmentation and Forecast to 2023

Market Scenario

Agnosia is a rare neurological condition in which an individual may face difficulty to process sensory information like recognizing a familiar person, sound or object. It is due to occurrence of lesions in the brain. Medical conditions such as dementia, stroke, head injury or any other neurological condition may lead to development of agnosia. Moreover, there are several conditions that may cause brain lesions and are associated with agnosia.

People suffering from agnosia can still interact with others normally. As such agnosia affects a single pathway when brain suffers a certain damage. The pathway might connect primary sensory areas that store information and knowledge. The primary sensory regions mainly include visual or auditory cortices. According to the World Health Organization (WHO) estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies.

Brain imaging techniques such as CT or MRI with or without angiographic protocols is required to characterize a central lesion such as hemorrhage, infarct or mass and also might check medical history of the patient and atrophy suggesting a degenerative disorder.

Many individuals suffering from agnosia can still retain their cognitive abilities, such as reading and basic math. The condition affects everyone differently but it can significantly impact the quality of life.

The cause of this disorders may precede the development of primary visual agnosia. Some causes of agnosia include diseases such as Alzheimer’s, Pick’s disease, Balint’s syndrome.  Alzheimer’s is a common, progressive, degenerative brain disorder affecting memory, thought, and language. Pick’s disease is also a degenerative neurological disorder that closely resemble the symptoms of Alzheimer’s disease. Balint’s syndrome is a rare neurological disorder characterized by the inability to voluntarily look at objects to the side. Individuals often cannot read, grasp or view one’s surroundings as a whole (simultanagnosia).

Some of the most probable causes of this disease are dementia, carbon monoxide poisoning, encephalitis, traumatic brain injuries and strokes. Physical examination is performed to detect any primary deficits in individual related to senses or inability to infer any test for agnosia.  According to WHO, the total number of people with dementia worldwide is projected to nearly double every 20 years, to 65.7 million in 2030 and 115.4 million in 2050. The total number of new cases of dementia each year is nearly 7.7 million worldwide, implying one new case every four seconds.

There is no specific treatment for agnosia. If doctors are able to identify the cause, the treatment will be tailored to the specific problem. For example, if an abscess is causing agnosia, the doctor may prescribe antibiotics and refer for a surgery to drain the abscess. Rehabilitation with speech or occupational therapists can help patients learn to compensate for their deficits.

Organizations such as the National Institute of Neurological Disorders and Stroke (NINDS) collects and disseminates research information related to neurological disorders. Furthermore, the National Organization for Rare Disorders (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.

The global market of agnosia treatment is expected to grow at a CAGR of approximately 7.2% during the forecast period 2017-2023.

Key Players

Some of key the players in the global agnosia treatment market are B. Braun Melsungen (Germany), Pfizer Inc. (U.S.),  Lupin ltd. (India), Fujifilm Holdings (Japan), GE Healthcare (U.S.), Siemens Healthcare(U.S.), Philips Healthcare (U.S.), F. Hoffmann-La Roche AG (Switzerland) , Aurobindo Pharma Ltd (India), Sandoz GmBH (Austria), Stellar- Bio Labs (India), Fresenius Kabi Ipsum SRL (Italy), Zhuhai United Laboratories Co Ltd (China), Cspc Zhongnuo Pharmaceutical Shijiazhuang Co Ltd (China), IPCA Labs ltd. (India) and others.

Segmentation

The agnosia treatment market is segmented on the basis of is segmented on the basis of diagnosis, causes, type, and treatment.

On the basis of diagnosis it is segmented into Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and others.

On the basis of causes it is segmented into Alzheimer's disease, Pick's disease, MELAS, Balint's syndrome.

On the basis of the type, it is segmented into auditory agnosia, gustatory agnosia, olfactory agnosia, tactile agnosia, visual agnosia, and others. Others is further segmented into prosopagnosia and anosognosia

On the basis of treatment, it is segmented into surgery, antibiotics for cerebral absess and radiation of brain tumor. Antibiotics for cerebral absess is further segmented into Ceftriaxone and Cefotaxime+metronidazole

Regional Analysis

The global agnosia treatment market consists of countries namely America, Europe, Asia Pacific, and the Middle East & Africa.

North America dominated the global agnosia treatment market owing to the increasing healthcare expenditure. The increasing incidence of accidents and brain injury is leading to development of new treatment methods are some of the driving factors responsible for the growth of the global agnosia treatment market.

Europe holds the second position in the global agnosia treatment owing to the government support for research & development and availability of funds for research. People with agnosia can benefit from speech and occupational therapy provided by the various European medical organisations such as Alzheimer Europe, and the European Conference on Visual Perception (ECVP) to learn how to deal with this impairment in their daily life.

Asia Pacific is the fastest growing agnosia treatment owing to the presence of rapidly developing healthcare technology, increasing stressful life, and high healthcare expenditure. Furthermore in the Middle East & Africa the spending for healthcare was also increased. The Middle East & Africa holds the least share of the market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa.

Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/agnosia-treatment-market-5045  

  
About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Latest Study Offers Detailed Insights on Anoxia Market 2018

Market Scenario

Anoxia is a condition that occurs due to complete loss of oxygen in body or brain which leads to various cognitive problems, and disabilities. It is considered as a severe cause of hypoxia. The most common causes of anoxia are respiratory arrest, drowning, carbon monoxide inhalation, illegal drug use, brain tumors, heart arrhythmia, suffocation, compression of the trachea, heart attack, and many others. Anoxic brain injury is also known as hypoxic-anoxic injury (HAI) or cerebral hypoxia. There are different types of anoxia, and each has an internal, and external causes. For instance, anemic anoxia occurs when blood is unable to carry enough oxygen to keep organs functioning properly, whereas, stagnant anoxia occurs when blood doesn’t reach brain or other body parts properly. Cardiovascular events such as, heart attack, cardiac arrhythmia, heart failure, and stroke, are the most common causes of stagnant anoxia. Anoxic anoxia usually at high altitudes. According to a study published in the Neural Regeneration Research journal, it is found that the with the increasing altitude partial pressure of oxygen falls which results in anoxic challenge to the person ascending to high altitudes.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/4989

Short-term memory loss, poor performance in executive functions, anomia, and visual disturbances are the commonly known cognitive problems associated with anoxia, whereas, physical problems include ataxia (lack of coordination), apraxia (inability to do common tasks), movement disorders, quadriparesis, and headaches.

Notably, rising cases of cardiac arrest is the key factor driving the anoxia market. According to a study published in the Critical Care journal in 2017, it is found that hypoxic ischemic brain injury (HIBI) is an outcome of cardiac arrest. It is stated that HIBI is the major cause of death in 23% of out-of-hospital cardiac arrest, and in 68% of inpatient cardiac arrest.

Various other factors such as, increasing awareness among people, increasing government assistance, and improvement in regulatory framework continuously contribute to the growth of the global anoxia market.

Despite these drivers, there are some issues associated with anoxia market. Challenges in research and development, and poor healthcare system in low and middle income countries may hinder the growth of market to an extent.

It is estimated that anoxia market is expected to grow at a CAGR 5.4% during the forecast period of 2017-2023.

Segmentation

The anoxia market is segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of type, market is segmented into anemic anoxia, toxic anoxia, stagnant anoxia, and anoxic anoxia.

On the basis of diagnosis, market is classified into blood tests, MRI (magnetic resonance imaging), CT or CAT scan (computerized axial tomography), evoked potential tests, and EEG (electroencephalogram).

On the basis of treatment, market is classified into cardiopulmonary resuscitation (CPR), rehabilitation therapies, and medication. Rehabilitation therapies is further segmented into speech therapy physical therapy, occupational therapy, recreational therapy, and adaptive equipment training. Medication is also further classified into ammonia reducer, anticonvulsant, steroids, vitamin, and others.

On the basis of end-users, market is segmented into hospital & clinics, diagnostic centers, research institutes, rehabilitation Centers, and others.

Regional Analysis

The Americas dominate the anoxia market owing to the rise in awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention, in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.

Europe holds the second position in anoxia market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe region.

Asia Pacific is the fastest growing anoxia market owing to the huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare, in the years 2015 to 2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than expenditure of 2014–15.

The Middle East & Africa has the lowest market for anoxia due to lack of technical knowledge and poor medical facilities.

Key Players

Some of key the players in the anoxia market are Pfizer, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc,, Cephalon Inc., Shire, UCB S.A, and others.

        

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Acute Care EHR Market 2018 Share, Trend, Segmentation and Forecast to 2023

Acute care EHR is different from its traditional counterparts. The acute care EHR allows healthcare professionals to collect, preserve and access vital patient clinical data in acute care and ambulatory care settings. Market Research Future (MRFR) perceives the global acute care EHR market to register a CAGR of 7% over the forecast period of 2017-2023.

The global acute care EHR market derives much of its growth from the surging incidences of chronic diseases on a global scale. In recent years, the prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disease have been on the rise which has consequently raised the number of healthcare institutions. Growth in a number of hospitals and other medical centers have created massive demand for management of patient data which boosts the growth of the global acute care EHR market. The rise in global geriatric population is also a contributing factor to the growth of the global acute care EHR market. The aged population who are more susceptible to suffer from chronic diseases have induced high demand for remote monitoring of geriatric patient data. Factors such as development in healthcare IT, technological advancements and expanding expenditure on healthcare act as a plus for the growth of the market. On the contrary, the growth of the global acute care EHR market might be restrained by high costs associated with acute care EHR solutions which might limit the growth of the market in price-sensitive market. Furthermore, towering costs of healthcare devices and treatments are also likely to hinder market growth.

Segmentation

The global acute care EHR market has been segmented based on deployment, application, and end user.

By deployment, the global acute care EHR market has been segmented into On-Premises based and Web-based.

By application, the global acute care EHR market has been segmented into personal care, pharmaceuticals, and others.

By end user, the global acute care EHR market has been segmented into hospital, ambulatory care, and others.

Regional Analysis

By region, the global acute care EHR market has been segmented into the Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).

The Americas account for the lion's share of the global acute care EHR market. Robust healthcare sector, a strong economy and massive expenditure on healthcare spur the market in the Americas. The region is a frontrunner in the adoption of advanced healthcare technologies. In addition, the rapid expansion of patient pool and rise in global geriatric population also supports the growth of the Americas market.

Europe is the second largest market for acute care EHR driven by the availability of funds, strong government support, and the presence of developed economies such as the UK, France, and Germany. Augmenting need for better management of healthcare devices and platform support the growth of the Europe acute care EHR market.

APAC is slated to be the fastest growing market for acute care EHR. Growing prevalence of chronic diseases and rising patient population stimulate the growth of the APAC market. Additionally, increasing number of hospitals, clinics and other healthcare centers across the region, increasing expenditure on healthcare and rapid economic growth are other driving factors.

The MEA market is anticipated to account for the least share of the global acute care EHR market. Lack of funds, limited availability of medical facilities and poor economic conditions, especially in Africa restrict the growth of the market. The Middle East market is likely to showcase positive growth pattern over the forecast period.

Competitive Landscape

The noteworthy players in the global acute care EHR market include Epic Systems Corporation (U.S.), Evident (CPSI) (U.S.), eClinicalWorks (U.S.), Medhost (U.S.), Athenahealth (RazorInsights) (U.S.), IBM (U.S.), Vitera Healthcare Solutions (U.S.), Meditech (U.S.), McKesson Corporation (U.S.), Allscript (U.S.), Cerner Corporation (Siemens) (U.S.), Healthland (U.S.), and General Electric Company (U.S.).

Industry Updates

• In November 2018, ResMed, a company that specializes in connected devices and remote monitoring for sleep apnea and respiratory illnesses announced the acquisition of MatrixCare’s post-acute care EHR solution for USD 750 million.

• In December 2018, Allscripts, a provider of healthcare solutions, announced selling of its stake in post-acute care EHR vendor Netsmart to TA Associates and GI Partners, both private equity firms for a total amount of USD 525 million.

Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/acute-care-ehr-market-4930

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Picture Archiving and Communications Systems Market 2018 Analysis, Opportunities and Forecast to 2023

Market Scenario:

Picture Archiving and Communication System (PACS) is a modality of the medical imaging technology used specifically for image transmission from the site of image acquisition to other locations. The technology is convenient to access multiple modalities such as radiographs, CT scan, MRI, ultrasound, and others.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/5833

The increasing prevalence of chronic diseases and the growing geriatric population are the key factors driving the Picture Archiving and Communication System (PACS) market. The increasing burden of chronic diseases has been observed in different parts of the world. Population in the low socio-economic group is mostly found to get affected by these chronic diseases. According to the report published in the Centers for Disease Control and Prevention (CDC) in 2017, nearly 92.1 million adults are dealing with at least one type of cardiovascular disease. The prevalence of type-2 diabetes, obesity, and cardiovascular diseases has increased rapidly in the recent years, suggested by a study published in the BMC Public Health in 2017.

Various other factors such as supportive investments and funds provided by government and private bodies, rising demand for early diagnosis, technological advancements in the medical imaging devices, rising incidence of cancer, improving regulatory framework, growing research funding, unmet medical needs, rising competition among market players, and increasing government assistance are continuously contributing to the growth of the global PACS market.

Despite these drivers, there are some issues associated with the PACS market. The high cost associated with the technology, lack of healthcare insurance, lack of awareness, and poor healthcare system in low- and middle-income countries may hamper the growth of the market.

It is estimated that the Picture Archiving and Communications Systems (PACS) market is expected to grow at a CAGR 7.0% during the forecast period of 2017–2023.

Segmentation

The global Picture Archiving and Communications Systems (PACS) market is segmented on the basis of type, component, imaging type, delivery mode, and end-user.

On the basis of type, the market is classified as oncology PACS, cardiology PACS, dental PACS, orthopedics PACS, and others.

On the basis of components, the market is classified as hardware, software, and services. The hardware segment is further classified as access devices, peripherals, servers, storage devices, and networking devices. The services segment is further classified as consulting, implementation services, post-sales and maintenance services, and training services.

On the basis of the type of imaging type, the market is classified as Magnetic Resonance Imaging (MRI), Computed Tomography (CT), nuclear imaging, X-ray, and ultrasound.

On the basis of end-user, the market is classified as hospitals and clinics, healthcare centers, imaging centers, diagnostic centers, clinical research institutions, and others.

On the basis of delivery mode, the market is classified as cloud-based (SAAS) delivery mode, web-hosted (On-Demand) delivery mode, and on-premise mode.

Regional Analysis

Radiology imaging solutions have generated a significant return on its healthcare IT investment by implementing Exa’s Voice Recognition in place of traditional transcriptionists, and their productivity has increased by 400%.           

The Americas dominates the Picture Archiving and Communications Systems (PACS) market owing to the rising demand for early diagnosis, rising prevalence of chronic diseases, well-developed technology, high healthcare expenditure, and the presence of leading players. Owing to the rising demand for imaging devices, various market players are coming up with advanced technology. For instance, on March 26, 2018, Singular Medical Technologies (SMT), the U.S. based technology company announced two new additions to its PACStation suite of products. The PACStation-GO is a fully functional reading workstation, with two full-size diagnostic monitors and is completely portable.

Europe holds the second position in the Picture Archiving and Communications Systems (PACS) market. It is expected that the funding towards research and development expenditure and increasing competition among marketers are likely to drive the European market.

Asia Pacific is the fastest growing Picture Archiving and Communications Systems (PACS) market owing to a huge patient pool, increasing demand for diagnosis, and development in the healthcare IT sector. According to IBEF, the Healthcare Information Technology (IT) market was valued at USD 1 billion in 2016 which is estimated to grow 1.5 times by 2020.

The Middle East and Africa holds the lowest share of the global Picture Archiving and Communications Systems (PACS) market due to low development, lack of technical knowledge, and poor medical facilities.

Key Players

Some of the key players in the global Picture Archiving and Communications Systems (PACS) market are Advanced Data Systems, Agfa-Gevaert N.V., Allscripts Healthcare Solutions, Inc., ALTA VISTA TELERADIOLOGY, Argus Radiology, Avreo, Inc., Brit Systems, Comarch SA, Cybernet Medical Corporation, FujiFilm Medical Systems, GE Healthcare, Global Diagnostics, INFINITT Healthcare, Konica Minolta Healthcare Americas Inc., McKesson Corporation,Inc., ONRAD, Inc., Pacshealth, LLC, PERFECT IMAGING, LLC, RamSoft, Inc., Radiology Imaging Solutions, Scimage, Inc., Sectra Imtec AB, Sectra Imtec AB, Siemens Healthineers, Singular Medical Technologies, StatRad, LLC, Telediagnostics Services Pvt. Ltd., Telerad Tech Private Limited, Virtual Radiology (vRAD), and others

Browse Complete 100 Pages Premium Research Report Enabled with 87 Respective Tables and Figures at @ https://www.marketresearchfuture.com/reports/picture-archiving-communications-systems-market-5833

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com